| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/21/2002 | WO2001028516A3 Sustained-release formulations for treating cns-mediated disorders |
| 02/21/2002 | WO2001026658A3 Topical nasal treatment using desloratadine |
| 02/21/2002 | WO2001019158A3 An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems |
| 02/21/2002 | WO2001003649A3 Compositions and methods for the treatment of parkinson's disease |
| 02/21/2002 | WO2000078355A3 Biologically active materials |
| 02/21/2002 | WO2000069875A9 C-2 modified erythromycin derivatives |
| 02/21/2002 | WO2000067740A9 Aminoguanidine for treating glaucomatous optic neuropathy |
| 02/21/2002 | WO2000067737A9 USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION |
| 02/21/2002 | WO2000054729A8 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 02/21/2002 | US20020022816 Device |
| 02/21/2002 | US20020022738 Solubility makes it possible to manufacture a solution of higher concentration of the compound and high-dosage drug product |
| 02/21/2002 | US20020022729 Pyridylfuran and pyridylthiophene compounds |
| 02/21/2002 | US20020022718 Genes identified as required for proliferation of E. coli |
| 02/21/2002 | US20020022668 Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections |
| 02/21/2002 | US20020022667 For inducing or maintaining anesthesia or sedation in a patient |
| 02/21/2002 | US20020022665 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 02/21/2002 | US20020022664 For therapy of sub-dermal plaque or scar tissue formation or accumulations, such as Peyronie's disease, Dupuytren's contracture, Ledderhose Fibrosis, scars, hemangiomas, and lipoederma ("cellulite") |
| 02/21/2002 | US20020022663 For producing analgesia in a warm blooded animal |
| 02/21/2002 | US20020022662 Enantiomers of O-desmethyl venlafaxine |
| 02/21/2002 | US20020022661 Methods for treating multiple sclerosis |
| 02/21/2002 | US20020022660 For disinfecting surfaces, long-lasting antimicrobial activity |
| 02/21/2002 | US20020022658 Methods for selectively occluding blood supplies to neoplasias |
| 02/21/2002 | US20020022657 Methods for modulating neuronal cell death |
| 02/21/2002 | US20020022655 Leukemic cell growth inhibiting method |
| 02/21/2002 | US20020022654 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 02/21/2002 | US20020022653 Cannabinoid drugs |
| 02/21/2002 | US20020022652 Methylnogarol compositions and uses thereof |
| 02/21/2002 | US20020022650 Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders |
| 02/21/2002 | US20020022649 Stable pharmaceutical formulation |
| 02/21/2002 | US20020022648 Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists |
| 02/21/2002 | US20020022646 Method for systhesizing leflunomide |
| 02/21/2002 | US20020022645 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor |
| 02/21/2002 | US20020022644 Topical ocular administration of a therapeutically effective amount of a prostaglandin related compound, the improvement to eliminate or reduce potential pigmentation of the iris of a treated eye occurring by long-term topical application |
| 02/21/2002 | US20020022643 1,1- and 1,2-disubstituted cyclopropane compounds |
| 02/21/2002 | US20020022642 As nitric oxide synthase (NOS) inhibitors, used in therapy and prophylaxis of central nervous system disorders, inflammatory disorders, septic shock and other disorders |
| 02/21/2002 | US20020022640 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 02/21/2002 | US20020022639 Packaging regimen of pseudoephedrine hydrochloride and fexofenadine hydrochloride |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022636 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| 02/21/2002 | US20020022635 For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration |
| 02/21/2002 | US20020022634 Method for treating alcohol intoxication and alcohol abuse |
| 02/21/2002 | US20020022631 Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase |
| 02/21/2002 | US20020022630 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands |
| 02/21/2002 | US20020022629 A new class of quinolone antibiotic (e.g., moxifloxacin) is useful for treating otic, opthalmic or nasal infections attributed to a microbacterium species selected from microbacterium otitidis or microbacterium alconae |
| 02/21/2002 | US20020022628 Useful as metalloproteinase inhibitor; piperazino-sulfonamide or piperidino-sulfonamide compound |
| 02/21/2002 | US20020022627 Inhibition of cyclooxygenase-2activity |
| 02/21/2002 | US20020022625 Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments |
| 02/21/2002 | US20020022623 A substituted hydroxyethylene compound useful for treating Alzheimer's disease, mild cognitive impairment, Down's syndrome, herediatary cerebral hemmorrhage with amyloidosis, degenerative dementia |
| 02/21/2002 | US20020022622 Administering effective amount of oxalzole, thiazole or imidazole derivatives to cure diseases associated with protein aging |
| 02/21/2002 | US20020022620 Reverse-turn mimetics and methods relating thereto |
| 02/21/2002 | US20020022619 Administering to the mammal suffering from anxiety, depression and other disorders related to excessive corticotropin releasing factor an effective amount of tricyclic pyridine or pyrimidine derivatives |
| 02/21/2002 | US20020022618 Administering to a mammal for the inducement of sphincter continence an effective amount of an indole derivatives |
| 02/21/2002 | US20020022617 Methods for increasing nitric oxide synthase activity |
| 02/21/2002 | US20020022616 Azepino[4,5-b]pyrano[3,2-e]indoles |
| 02/21/2002 | US20020022615 Cyclic oxyguanidine protease inhibitors |
| 02/21/2002 | US20020022613 Administering to a mammal to inhibit bone prosthtic (dental)degeneration an effective amount of a benzyl-1H-indole derivative or salts |
| 02/21/2002 | US20020022612 Nitrogen containing heterocyclic compounds useful as anticoagulants |
| 02/21/2002 | US20020022611 Wrinkling modifiers |
| 02/21/2002 | US20020022610 Compositions and methods for treating bacterial infections |
| 02/21/2002 | US20020022609 Orally active androgens |
| 02/21/2002 | US20020022608 Use of tetracycline derivatives in treating multiple sclerosis |
| 02/21/2002 | US20020022605 Cyclamine sulfonamides as beta-3 adrenergic receptor agonists |
| 02/21/2002 | US20020022604 4-oxo-4h-pyran derviatives; use as inhibitors of serine proteases; anticoagulants; treating thrombotic conditions including coronary artery and cerebrovascular diseases |
| 02/21/2002 | US20020022603 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity |
| 02/21/2002 | US20020022602 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 02/21/2002 | US20020022600 Azt derivatives exhibiting spermicidal and anti-viral activity |
| 02/21/2002 | US20020022599 Methods of modulating drug clearance mechanisms by altering SXR activity |
| 02/21/2002 | US20020022598 Agent for inducing apoptosis |
| 02/21/2002 | US20020022596 Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them |
| 02/21/2002 | US20020022589 Administering a scytoneman compound for treating, preventing, or inhibiting a tissue hyperplasia in a subject; antiprotozoa agents |
| 02/21/2002 | US20020022587 Administering a compound which increases a transient potassium (K+ ) current in the excitable cells of a patient; losartan, saralasin for example |
| 02/21/2002 | US20020022586 Administering a pyrimidine analog (a common chemotherapeutic) and a cyclic GMP (cGMP)-specific phosphodiesterase (PDE) inhibitor to reduce side effects of treatment with a pyrimidine analog |
| 02/21/2002 | US20020022257 Three-dimensional structure and crystallization method of ribosome recycling factor (RRF) |
| 02/21/2002 | US20020022245 Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
| 02/21/2002 | US20020022218 Methods for the identification of compounds useful for the treatment of disease states medicated by prostaglandin D2 |
| 02/21/2002 | US20020022215 Inactivation of small non-enveloped viruses and other microbial pathogens by porphyrins |
| 02/21/2002 | US20020022062 Using coffee bean extract |
| 02/21/2002 | US20020022061 Anticoagulant mixture |
| 02/21/2002 | US20020022058 Oral consumable; mixture of therapy and nutrients |
| 02/21/2002 | US20020022056 Bioavailability; core overcoated with hydrophilic permeable exterior coatings; controlling particle sizes |
| 02/21/2002 | US20020022054 Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
| 02/21/2002 | US20020022047 Implant device with a retinoid for improved biocompatibility |
| 02/21/2002 | US20020022039 Food, cosmetics, drugs; cooling skin, mouth |
| 02/21/2002 | US20020022038 Polymeric and, or wax envelopes |
| 02/21/2002 | US20020022035 Genetic engineering; deactivating toxin |
| 02/21/2002 | US20020022034 Therapeutic DNA vaccination |
| 02/21/2002 | US20020022031 Immunotherapy for chronic myelocytic leukemia |
| 02/21/2002 | US20020022027 Complexing to polypeptides; antiproliferation agent |
| 02/21/2002 | US20020022022 Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors |
| 02/21/2002 | US20020022012 Stability, nontoxic; anthrax |
| 02/21/2002 | US20020022005 Compositions for treating cystic fibrosis |
| 02/21/2002 | US20020022003 Method and composition for the treatment of cancer by the enzymantic conversion of soluble radioactive toxic precipitates in the cancer |
| 02/21/2002 | US20020020784 Flexible kite |
| 02/21/2002 | EP1143935A3 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 02/21/2002 | DE10039998A1 Neue substituierte Diareno-azepin-Derivate als Integrin Liganden New substituted Diareno-azepine derivatives as integrin ligands |
| 02/21/2002 | DE10039199A1 Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen Combination preparations of ERß a selective estrogen and a SERM or antiestrogen |
| 02/21/2002 | DE10039063A1 Kosmetische und dermatologische Zubereitung mit einem Gehalt an Cyclodextrinen zur Beseitigung von Sebum Cosmetic and dermatological composition containing cyclodextrins on the Elimination of sebum |
| 02/21/2002 | DE10038639A1 New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |
| 02/21/2002 | DE10037046A1 Verwendung von N-Oleoylethanolamin zur Behandlung der Schuppenflechte (Psoriasis) Use of N-oleoylethanolamine for the treatment of psoriasis (psoriasis) |
| 02/21/2002 | DE10035189A1 Arzneimittel zur oralen Applikation mit einem Gehalt an 3-N-Formylhydroxylaminopropylphosphonsäureestern oder 3-N-Acetylhydroxylaminopropylphosphonsäureestern als Wirkstoff Pharmaceuticals for oral application with a content of 3-N-Formylhydroxylaminopropylphosphonsäureestern or 3-N-Acetylhydroxylaminopropylphosphonsäureestern as an active ingredient |